U.S., Sept. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07824986) titled 'A Phase 3 Trial in Advanced Epithelioid Mesothelioma' on Sept. 01.
Brief Summary: This randomized, open-label, multicenter Phase 3 trial will compare VT3989 with Investigator's choice of gemcitabine or vinorelbine in adults with advanced epithelioid pleural mesothelioma whose disease progressed after prior platinum-based systemic chemotherapy and immunotherapy.
Study Start Date: Dec. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Pleural Mesothelioma
Mesothelioma
Intervention:
DRUG: VT3989
* 100 mg orally once daily for 2 weeks on treatment followed by 2 weeks off treatment (2W/2W) in each 4-week cycle
DRUG: gemcitabine
* ...